3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Pancreatic Neoplasms
3
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Synovitis, Pigmented Villonodular
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Head and Neck Neoplasms
1
Glioma
1
Giant Cell Tumor of Tendon Sheath
1
Carcinoma, Hepatocellular
1
Advanced Pancreatic Cancer
1
Advanced Malignancies
1
Interventions
Cisplatin
75
Cetuximab
63
Radiotherapy
38
pembrolizumab
29
Radiotherapy, Intensity-Modulated
28
Carboplatin
25
Fluorouracil
24
Docetaxel
24
Paclitaxel
19
Erlotinib Hydrochloride
13
Nivolumab
12
Radiation
10
Pemetrexed
10
durvalumab
8
Gemcitabine
8
Drug Therapy
8
Bevacizumab
7
zalutumumab
6
Surgical Procedures, Operative
6
Panitumumab
6
Lapatinib
6
Everolimus
6
Albumin-Bound Paclitaxel
6
130-nm albumin-bound paclitaxel
6
epacadostat
5
Standard of Care
5
Oxaliplatin
5
Gefitinib
5
Afatinib
5
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Head and Neck Neoplasms
×
cabiralizumab
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts